Login to Your Account



Clinic Roundup


Thursday, June 23, 2011
Threshold Pharmaceuticals Inc., of Redwood City, Calif., completed patient enrollment in its Phase II study of TH-302, a small-molecule tumor-selective hypoxia-activated prodrug, in pancreatic cancer. The company expanded the enrollment target from 165 patients to at least 200, which increases the statistical power of the study to greater than 80 percent. The trial is testing TH-302 in combination with gemcitabine in patients with first-line disease, and the primary endpoint is progression-free survival.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription